{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:25:13Z","timestamp":1794273913044,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Netherlands Heart Foundation","doi-asserted-by":"publisher","award":["2019T049"],"award-info":[{"award-number":["2019T049"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["825828"],"award-info":[{"award-number":["825828"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omtn.2026.102939","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:09:51Z","timestamp":1776874191000},"page":"102939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficiency and immunogenicity of lipid nanoparticle-mediated cardiac mRNA delivery are lipid composition-dependent"],"prefix":"10.1016","volume":"37","author":[{"given":"Maria C.I.","family":"Labonia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol Escud\u00e9","family":"Martinez de Castilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra H.","family":"van der Kraak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike A.D.","family":"Brans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangbing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia C.A.","family":"de Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn S.","family":"de Voogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Schiffelers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.G.","family":"Sluijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7059-8920","authenticated-orcid":false,"given":"Pieter","family":"Vader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102939_bib1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart Disease and Stroke Statistics\u20142020 Update: A Report From the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2026.102939_bib2","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102939_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10557-020-07051-4","article-title":"Modified mRNA as a Therapeutic Tool for the Heart","volume":"34","author":"Kaur","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.omtn.2026.102939_bib4","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.15585\/mmwr.mm7037e3","article-title":"Effectiveness of COVID-19 mRNA Vaccines Against COVID-19\u2013Associated Hospitalization \u2014 Five Veterans Affairs Medical Centers, United States, February 1\u2013August 6, 2021","volume":"70","author":"Bajema","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.omtn.2026.102939_bib5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2026.102939_bib6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102939_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.201700375","article-title":"State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery","volume":"2","author":"Evers","year":"2018","journal-title":"Small Methods"},{"key":"10.1016\/j.omtn.2026.102939_bib8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2026.102939_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.omtn.2026.102939_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2021.12.027","article-title":"Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)","volume":"344","author":"Parhiz","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102939_bib11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jconrel.2024.04.018","article-title":"Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration","volume":"369","author":"Labonia","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102939_bib12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.102939_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.omtn.2026.102939_bib14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/08971900211009650","article-title":"Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273","volume":"35","author":"Teo","year":"2022","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.omtn.2026.102939_bib15","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3390\/vaccines11111635","article-title":"Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines ComirnatyTM (Pfizer) and SpikevaxTM (Moderna): A Comparative Study of the Particulate","volume":"11","author":"Hermosilla","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2026.102939_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","article-title":"Impact of lipid nanoparticle size on mRNA vaccine immunogenicity","volume":"335","author":"Hassett","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102939_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omtm.2023.06.005","article-title":"Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues","volume":"30","author":"Chander","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.102939_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115175","article-title":"The immunostimulatory nature of mRNA lipid nanoparticles","volume":"205","author":"Sharma","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.102939_bib19","first-page":"188","article-title":"Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals. Commun","volume":"6","author":"Connors","year":"2023","journal-title":"Biol"},{"key":"10.1016\/j.omtn.2026.102939_bib20","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.102939_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2023.06.025","article-title":"Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax\u00ae against COVID-19 in nonhuman primates","volume":"360","author":"Zamani","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.102939_bib22","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0021-9258(18)33302-7","article-title":"Tissue distribution, structural characterization, and biosynthesis of Mac-3, a macrophage surface glycoprotein exhibiting molecular weight heterogeneity","volume":"258","author":"Ho","year":"1983","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102939_bib23","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/cid\/ciab707","article-title":"Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model","volume":"74","author":"Li","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.omtn.2026.102939_bib24","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.102939_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241248956","article-title":"Potential Application of Modified mRNA in Cardiac Regeneration","volume":"33","author":"Wang","year":"2024","journal-title":"Cell Transplant."},{"key":"10.1016\/j.omtn.2026.102939_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","article-title":"Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial","volume":"18","author":"Anttila","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.102939_bib27","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2026.102939_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2026.102939_bib29","article-title":"Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape Without Side Effects","author":"Omo-Lamai","year":"2024","journal-title":"Preprint"},{"key":"10.1016\/j.omtn.2026.102939_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102939_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202206968","article-title":"Biodegradable Cationic and Ionizable Cationic Lipids: A Roadmap for Safer Pharmaceutical Excipients","volume":"19","author":"J\u00f6rgensen","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.omtn.2026.102939_bib32","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and Lipid Derivatives for RNA Delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.omtn.2026.102939_bib33","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2026.102939_bib34","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1189\/jlb.0809546","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo","volume":"89","author":"Khajah","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.omtn.2026.102939_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1083\/jcb.39.1.152","article-title":"HUMAN WOUND REPAIR","volume":"39","author":"Ross","year":"1968","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2026.102939_bib36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: The phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.omtn.2026.102939_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jconrel.2022.01.027","article-title":"Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles","volume":"343","author":"Evers","year":"2022","journal-title":"J. Contr. Release"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:18:24Z","timestamp":1794273504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2162253126001101"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102939","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficiency and immunogenicity of lipid nanoparticle-mediated cardiac mRNA delivery are lipid composition-dependent","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102939"}}